In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
News|Videos|January 17, 2025
The Most Common Challenges in Treating Bipolar Disorder
Author(s)Mark Jankelow, MSN, PMHNP-BC
Key Takeaways
- Patient insight is crucial, as many do not recognize their bipolar disorder, complicating treatment efforts.
- Differentiating between unipolar and bipolar depression is essential for accurate diagnosis and effective management.
The top 3 issues in treating bipolar disorder are...
Advertisement
CONFERENCE REPORTER
Mark Jankelow, MSN, PMHNP-BC, shares what he believes are the top challenges in treating bipolar disorder at the Real Psychiatry conference in Scottsdale, AZ. His top issues include (1) lack of insight on the part of the patient, or the patient not realizing they are affected by bipolar disorder, (2) recognizing the difference between unipolar depression and bipolar depression, and (3) keeping patients on their medication.
Mr Jankelow is an experienced board-certified psychiatric nurse practitioner who has worked in community mental health, the Colorado Department of Corrections, and is the owner of a Springbok Health, Inc.
Advertisement
Related to this article
Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5